Literature DB >> 1839986

Concentration of ethinyl estradiol in the serum of 31 young women following a treatment period of 3 months with two low-dose oral contraceptives in an intraindividual cross-over design.

W Kuhnz1, D Back, J Power, B Schütt, T Louton.   

Abstract

Two low-dose oral contraceptives, both containing the same dose of ethinyl estradiol (EE2) but different progestins (gestodene and desogestrel, respectively), were compared with respect to the relative bioavailability of EE2. The study was conducted with 31 women as an open intraindividual comparison with the ingestion of both preparations for 3 months, respectively. On days 1, 10 and 21 of the 1st, 3rd and 6th cycle, blood was sampled at 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 and 24 h following administration. The concentrations of EE2 were determined in the serum samples of each individual and the area under the serum concentration versus time curves, AUC (0-4 h) and AUC (0-24 h), were calculated. Corresponding parameters obtained on days 1, 10 and 21 of the 3rd and 6th month of treatment were compared on a statistical basis, and no differences were found. This result was in concordance with a previously performed study, where both formulations were administered to 18 women in a single-dose cross-over design. However, the results of the previous and the present study are at variance with the result of one other study, reporting higher EE2 levels in the serum of women taking the gestodene-containing formulation as compared to those taking the desogestrel-containing formulation.

Entities:  

Keywords:  Contraception; Contraceptive Agents; Contraceptive Agents, Estrogen; Contraceptive Agents, Female; Contraceptive Agents, Progestin; Contraceptive Methods; Desogestrel; Ethinyl Estradiol; Examinations And Diagnoses; Family Planning; Gestodene; Laboratory Examinations And Diagnoses; Oral Contraceptives; Oral Contraceptives, Combined; Oral Contraceptives, Low-dose

Mesh:

Substances:

Year:  1991        PMID: 1839986     DOI: 10.1159/000182110

Source DB:  PubMed          Journal:  Horm Res        ISSN: 0301-0163


  5 in total

1.  Influence of ethinylestradiol-containing combination oral contraceptives with gestodene or levonorgestrel on caffeine elimination.

Authors:  A Balogh; G Klinger; L Henschel; A Börner; R Vollanth; W Kuhnz
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

Review 2.  Gestodene. A review of its pharmacology, efficacy and tolerability in combined contraceptive preparations.

Authors:  M I Wilde; J A Balfour
Journal:  Drugs       Date:  1995-08       Impact factor: 9.546

3.  Tazarotene does not affect the pharmacokinetics and efficacy of a norethindrone/ethinylestradiol oral contraceptive.

Authors:  Zhiling Yu; Dale Yu; Patricia S Walker; Diane D-S Tang-Liu
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

Review 4.  Oral contraceptives. Are drug interactions of clinical significance?

Authors:  G M Shenfield
Journal:  Drug Saf       Date:  1993-07       Impact factor: 5.606

5.  Ursodeoxycholic acid does not affect ethinylestradiol bioavailability in women taking oral contraceptives.

Authors:  Ornella Baisini; Federica Benini; Felice Petraglia; Wilhelm Kuhnz; Santo Scalia; Hanns-Ulrich Marschall; Gabriele Brunetti; Horst-Dietmar Tauschel; Alberto Lanzini
Journal:  Eur J Clin Pharmacol       Date:  2004-09       Impact factor: 2.953

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.